Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 26929-26930 [2017-12124]
Download as PDF
26929
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
Control No. 0923–0054, expiration date
01/31/2017). The research goals for the
three activities in the protocol are pilotlevel investigations to evaluate and
characterize: The chemical composition
and use of crumb rubber infill in
synthetic turf using a convenience
sample of nine tire recycling
manufacturing plants and 40 facilities
that use synthetic turf fields (Activity 1);
The human exposure potential to
constituents in crumb rubber infill
among a convenience sample of 60 field
users (Activity 2); and collection of
biological specimens (blood and urine)
from 45 participants from Activity 2
(Activity 3).
By December, 2016, ATSDR and US
EPA completed Activity 1 which was
aimed at characterizing the chemical
composition and use of synthetic turf
fields with tire crumb rubber infill. The
agencies successfully consented and
sampled 40 synthetic turf fields with
crumb rubber infill across the United
States. The activities are reported in the
‘‘Status Report on the Federal Research
Action Plan on Recycled Tire Crumb
Used on Playing Fields and
Playgrounds,’’ which was released on
December 30, 2016.
During Activity 1, ATSDR and US
EPA obtained permission to return to
some of the participating fields to
complete the human exposure
characterization. Due to the limited time
constraints and field activity schedules,
ATSDR and US EPA chose to begin
Activity 2 data collection and Activity
3 specimen collection in 2017.
The agencies are submitting a new
information collection request (ICR) for
a one-year PRA clearance to complete
Activity 2 and Activity 3, now subtitled
‘‘Characterization of Exposure Potential
during Activities Conducted on
Synthetic Turf with Crumb Rubber
Infill.’’ This will be the first assessment
of activities conducted on synthetic turf
for the purpose of characterizing
potential exposure patterns. The study
will include persons who use synthetic
turf with crumb rubber infill (e.g.,
facility users) and who routinely
perform activities that would result in a
high level of contact to crumb rubber.
This will allow for the evaluation of
potential high-end exposures to
constituents in synthetic turf among this
group of users. The respondents will be
administered a detailed questionnaire
on activity patterns on synthetic turf
with crumb rubber infill. This
instrument, along with extant
videography of persons engaged in
activities of interest (see below), will be
used to characterize exposure scenarios,
including the nature and duration of
potential exposures.
The research study will screen a total
of 75 participants for eligibility. The
sample size for the Activity 2 exposure
characterization is 60 respondents. For
Activity 3, we will conduct an exposure
measurements sub-study among 45 of
the 60 respondents, including field
environmental sampling, personal air
monitoring, dermal sampling, and urine
and blood collection. Video data
collection of facility user activities will
be performed for a further subset of 24
of the Activity 2 respondents. It is likely
that some of the collection items will
not be analyzed in the current project
time frame but will be archived for
future analysis.
The total estimated annual time
burden requested for this research
activity equals 174 hours. There is no
cost to the respondents other than their
time in the study.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Adult/Adolescent Facility Users ......................
Facility
Eligibility Screening Script ..............................
Adult and Adolescent Questionnaire .............
Exposure Measurement Form .......................
Phlebotomist Safety Exclusion Questions
Form.
Eligibility Screening Script ..............................
Youth/Child Facility Users ...............................
Youth and Child Questionnaire ......................
Phlebotomist Safety Exclusion Questions
Form.
Exposure Measurement Form .......................
Parents/Guardians
Users.
of
Youth/Child
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2017–12061 Filed 6–9–17; 8:45 am]
asabaliauskas on DSKBBXCHB2PROD with NOTICES
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of a single-source supplement for
Funding Opportunity Announcement
(FOA) CK16–003, Pre-travel Health
Preparation of International Travelers:
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(in hours)
41
36
27
27
1
1
1
1
5/60
30/60
3
2/60
34
1
5/60
24
18
1
1
30/60
2/60
18
1
3
Expanding and Improving Data
Collection, Guidance, and Outreach.
Time and Date: 12:00 p.m.–2:00 p.m.,
EDT, July 18, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion and evaluation of a singlesource supplement application for ‘‘Pretravel Health Preparation of
E:\FR\FM\12JNN1.SGM
12JNN1
26930
Federal Register / Vol. 82, No. 111 / Monday, June 12, 2017 / Notices
International Travelers: Expanding and
Improving Data Collection, Guidance,
and Outreach’’, CK16–003.
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE., Mailstop E60, Atlanta,
Georgia 30333, Telephone: (404) 718–
8833.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–12124 Filed 6–9–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSKBBXCHB2PROD with NOTICES
World Trade Center Health Program
Scientific/Technical Advisory
Committee: Notice of Charter Renewal
This gives notice under Public Law
111–347 (The James Zadroga 9/11
Health and Compensation Act of 2010)
and the Federal Advisory Committee
Act (Pub. L. 92–463) of October 6, 1972,
that the World Trade Center Health
Program Scientific/Technical Advisory
Committee, Centers for Disease Control
and Prevention, Department of Health
and Human Services, has been renewed
for a 2-year period through May 12,
2019.
For information, contact Paul J.
Middendorf, Ph.D., Designated Federal
Officer, National Institute for
Occupational Safety and Health, Centers
for Disease Control and Prevention,
Department of Health and Human
Services, 2400 Century Parkway NE.,
Mail Stop E–20, Atlanta, Georgia 30345,
telephone 1 (888) 982–4748; email: wtcstac@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
VerDate Sep<11>2014
17:28 Jun 09, 2017
Jkt 241001
Prevention and the Agency for Toxic
Substances and Disease Registry.
should be received within 30 days of
this notice.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Proposed Project
ZEN Colombia Study: Zika in
Pregnant Women and Children in
Colombia—New—Pregnancy and Birth
Defects Task Force, National Center on
Birth Defects and Developmental
Disabilities, Centers for Disease Control
and Prevention (CDC).
[FR Doc. 2017–12125 Filed 6–9–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–17–17ABB]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, Washington, DC 20503 or by fax
to (202) 395–5806. Written comments
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Background and Brief Description
Zika virus (ZIKV) infection is a
mosquito-borne flavivirus transmitted
by Aedes species mosquitoes, and also
through sexual and mother-to-child
transmission; laboratory-acquired
infections have also been reported.
Evidence of human ZIKV infection was
observed sporadically in Africa and
Asia prior to 2007, when an outbreak of
ZIKV caused an estimated 5,000
infections in the State of Yap, Federated
States of Micronesia. Since then,
evidence of ZIKV has been found in 65
countries and territories, mostly in
Central and South America. Common
symptoms of ZIKV in humans include
rash, fever, arthralgia, and nonpurulent
conjunctivitis. The illness is usually
mild and self-limited, with symptoms
lasting for several days to a week;
however, based on previous outbreaks,
some infections are asymptomatic. The
prevalence of asymptomatic infection in
the current Central and South American
epidemic is unknown.
Although the clinical presentation of
ZIKV infection is typically mild, ZIKV
infection in pregnancy can cause
microcephaly and related brain
abnormalities when fetuses are exposed
in utero. Other adverse pregnancy
outcomes related to ZIKV infection
remain under study, and include
pregnancy loss, other major birth
defects, arthrogryposis, eye
abnormalities, and neurologic
abnormalities.
As the spectrum of adverse health
outcomes potentially related to ZIKV
infection continues to grow, large gaps
remain in our understanding of ZIKV
infection in pregnancy. These include
the full spectrum of adverse health
outcomes in pregnant women, fetuses,
and infants associated with ZIKV
infection; the relative contributions of
sexual transmission and mosquito-borne
transmission to occurrence of infections
in pregnancy; and variability in the risk
of adverse fetal outcomes by gestational
week of maternal infection or symptoms
of infection. There is an urgency to fill
these large gaps in our understanding
given the rapidity of the epidemic’s
spread and the severe health outcomes
associated with ZIKV to date.
E:\FR\FM\12JNN1.SGM
12JNN1
Agencies
[Federal Register Volume 82, Number 111 (Monday, June 12, 2017)]
[Notices]
[Pages 26929-26930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-12124]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of a
single-source supplement for Funding Opportunity Announcement (FOA)
CK16-003, Pre-travel Health Preparation of International Travelers:
Expanding and Improving Data Collection, Guidance, and Outreach.
Time and Date: 12:00 p.m.-2:00 p.m., EDT, July 18, 2017 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C.,
and the determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion and evaluation of a single-source supplement
application for ``Pre-travel Health Preparation of
[[Page 26930]]
International Travelers: Expanding and Improving Data Collection,
Guidance, and Outreach'', CK16-003.
Contact Person for More Information: Gregory Anderson, M.S.,
M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop
E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-12124 Filed 6-9-17; 8:45 am]
BILLING CODE 4163-18-P